About Senseonics Holdings, Inc. - Common Stock (SENS)
Senseonics Holdings is a biomedical company specializing in the development and commercialization of innovative glucose monitoring systems for people living with diabetes. The company's flagship product is a long-term implantable continuous glucose monitoring (CGM) device that is designed to provide real-time glucose data to users, enhancing their ability to manage their condition effectively. By combining advanced sensor technology with a commitment to patient care, Senseonics aims to improve the quality of life for individuals with diabetes through more accurate and convenient monitoring options. Read More
GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense® 365 CGM system.
GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah.
